Janus kinase 2 (JAK2) inhibitors in the treatment of multiple myeloma: modulating the myeloma immune microenvironment

被引：4
|
作者：
Giles, Hannah [1 ]
Pratt, Guy [1 ]
机构：
[1] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 192卷 / 03期
关键词：
JAK2; inhibitors; multiple myeloma; myeloma immune; microenvironment; FUNCTION IN-VITRO; CELL-FUNCTION; RUXOLITINIB; TOFACITINIB; EFFICACY; DISEASE;
D O I：
10.1111/bjh.17277
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：420 / 422
页数：3
相关论文
共 50 条
  • [21] Sphingosine kinase 2 and multiple myeloma
    Pyne, Nigel J.
    Pyne, Susan
    ONCOTARGET, 2017, 8 (27): : 43596 - 43597
  • [22] Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core
    Liosi, Maria-Elena
    Krimmer, Stefan G.
    Newton, Ana S.
    Dawson, Thomas K.
    Puleo, David E.
    Cutrona, Kara J.
    Suzuki, Yoshihisa
    Schlessinger, Joseph
    Jorgensen, William L.
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (10) : 5324 - 5340
  • [23] The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: Therapeutic implications
    Quintas-Cardama, Alfonso
    LEUKEMIA RESEARCH, 2013, 37 (04) : 465 - 472
  • [24] Preferential Inhibition of An Activated Form of Janus Kinase 2 (JAK2) by a Novel JAK2 Inhibitor, NS-018
    Nakaya, Yohei
    Naito, Haruna
    Homan, Juriko
    Sugahara, Seishi
    Horio, Tatsuya
    Niwa, Tomoko
    Shide, Kotaro
    Shimoda, Kazuya
    BLOOD, 2010, 116 (21) : 1672 - 1672
  • [25] The Immune Microenvironment in Multiple Myeloma: Friend or Foe?
    Lopes, Raquel
    Caetano, Joana
    Ferreira, Bruna
    Barahona, Filipa
    Carneiro, Emilie Arnault
    Joao, Cristina
    CANCERS, 2021, 13 (04) : 1 - 16
  • [26] Therapeutics to harness the immune microenvironment in multiple myeloma
    Ignatz-Hoover, James J.
    Driscoll, James J.
    CANCER DRUG RESISTANCE, 2022, 5 (03) : 647 - 661
  • [27] Dysregulations of the immune tumor microenvironment in multiple myeloma
    Cholujova, Dana
    Beke, Gabor
    Hideshima, Teru
    Klucar, Lubos
    Leiba, Merav
    Jamroziak, Krzysztof
    Richardson, Paul
    Kastritis, Efstathios
    Dorfman, David
    Anderson, Kenneth
    Jakubikova, Jana
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S251 - S251
  • [28] JAK2 inhibitors
    Hernandez Boluda, Juan Carlos
    Gomez, Montse
    Perez, Ariadna
    MEDICINA CLINICA, 2016, 147 (02): : 70 - 75
  • [29] CK2 Kinase Inhibitors Display Anti-Myeloma Effects and Antagonize Osteoclast Activity in Models of Multiple Myeloma Bone Marrow Microenvironment
    Manni, Sabrina
    Toscani, Denise
    Colpo, Anna
    Brancalion, Alessandra
    Zaffino, Fortunato
    Tubi, Laura Quotti
    Semenzato, Gianpietro
    Giuliani, Nicola
    Piazza, Francesco
    BLOOD, 2012, 120 (21)
  • [30] SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors
    Forsyth, Timothy
    Kearney, Patrick C.
    Kim, Byung Gyu
    Johnson, Henry W. B.
    Aay, Naing
    Arcalas, Arlyn
    Brown, David S.
    Chan, Vicky
    Chen, Jeff
    Du, Hongwang
    Epshteyn, Sergey
    Galan, Adam A.
    Huynh, Tai P.
    Ibrahim, Mohamed A.
    Kane, Brian
    Koltun, Elena S.
    Mann, Grace
    Meyr, Lisa E.
    Lee, Matthew S.
    Lewis, Gary L.
    Noguchi, Robin T.
    Pack, Michael
    Ridgway, Brian H.
    Shi, Xian
    Takeuchi, Craig S.
    Zu, Peiwen
    Leahy, James W.
    Nuss, John M.
    Aoyama, Ron
    Engst, Stefan
    Gendreau, Steven B.
    Kassees, Robert
    Li, Jia
    Lin, Shwu-Hwa
    Martini, Jean-Francois
    Stout, Thomas
    Tong, Philip
    Woolfrey, John
    Zhang, Wentao
    Yu, Peiwen
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (24) : 7653 - 7658
12345